NEW YORK – AbbVie on Tuesday announced a partnership with ConcertAI and Caris Life Sciences to advance its precision oncology pipeline and optimize cancer drug trials.
AbbVie will develop novel therapies with the help of Caris' real-world, multimodal clinical and genomic database and ConcertAI's research-grade clinical data. The drugmaker will also use ConcertAI and Caris' clinical network and laboratory capabilities together with artificial intelligence to improve oncology clinical trials and patient enrollment. The partners didn't disclose the financial details of the collaboration.
AbbVie is developing more than a dozen early-stage therapies alongside several late-stage candidates and is continuing research to expand the use of its approved cancer therapies, such as the BCL-2 inhibitor Venclexta (venetoclax), the BTK inhibitor Imbruvica (ibrutinib), and the recently approved bispecific antibody DuoBody CD3xCD20 (epcoritamab).
In November, AbbVie said it was speaking to health authorities about a potential accelerated approval for telisotuzumab-vedotin in c-Met-overexpressing, EGFR wild-type advanced non-small cell lung cancer.